MARAC Statement: Voxelotor (Oxbryta®) - Sickle Cell Disease …
WEB1 day ago · “Pfizer’s decision is based on the totality of clinical data that now indicate the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which require further assessment. ” [1].
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB4 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer decision to withdrawal sickle cell drug leaves patients
WEB3 days ago · Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to...
Pfizer withdraws sickle cell disease treatment on risk of …
WEB4 days ago · U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB4 days ago · OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells leading to hemolysis and hemolytic anemia, which are primary pathologies faced by...
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB4 days ago · Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths. The...
Sickle cell community scrambles after a Pfizer drug is pulled
WEB2 days ago · It had started last January, just shy of her 27th birthday, when she’d called to get a refill of a sickle cell drug called Oxbryta. There was some mix-up with her insurers; they wouldn’t pay...
FDA is alerting patients and health care professionals about the ...
WEB3 days ago · FDA approved Oxbryta under the accelerated approval pathway in 2019 for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
Pfizer withdraws sickle cell treatment due to safety concerns
WEB2 days ago · Pfizer has voluntarily withdrawn its sickle cell disease treatment Oxbryta (voxelotor) from the market due to safety concerns. The Food and Drug Administration (FDA) recommends clinicians stop prescribing the treatment and patients talk to their doctor about starting a different treatment.
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide …
WEB4 days ago · Pfizer PFE 0.14% said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its parent company Global Blood...
Skip to content